Impact of Vedolizumab on Bowel Urgency in Ulcerative Colitis: Post Hoc Analysis of the GEMINI 1, VISIBLE 1, and VARSITY Trials Authors: Angelina E Collins, Thais Gift, Edward Kim, Ian Robinson Published: 2026 ABSTRACT AbstractBackground and AimsBowel urgency is a particularly burdensome symptom for adults with ulcerative colitis. This post hoc analysis of 3 phase 3 studies evaluated the effects of vedolizumab on bowel urgency using selected items from the Inflammatory Bowel Disease Questionnaire (IBDQ).MethodsData were pooled from 3 phase 3 randomized trials: GEMINI 1 (NCT00783718), VISIBLE 1 (NCT02611830), and VARSITY (NCT02497469). Adults with moderate to severe ulcerative colitis who received vedolizumab or placebo and completed the IBDQ were included. Items Q11, Q16, and Q26 from the IBDQ were combined to create a bowel urgency composite score. Bowel urgency resolution was defined as the absence of symptoms across all 3 items. Primary outcomes were the change in bowel urgency composite score and the proportion of patients with bowel urgency resolution at week 52. Exploratory outcomes included change in bowel urgency composite score and bowel urgency resolution stratified by anti–tumor necrosis factor-α exposure status, disease activity, and treatment arm (intravenous vedolizumab once every 8 weeks vs placebo), and the relationship between bowel urgency and clinical and endoscopic outcomes.ResultsOverall, 1225 patients were included. Patients receiving vedolizumab had greater changes in bowel urgency composite scores than placebo overall and when stratified into subgroups. A greater proportion of patients in the vedolizumab group (44%) attained bowel urgency resolution than the placebo group (22%). Bowel urgency resolution at week 6 was significantly associated with attaining all clinical and endoscopic outcomes at week 6, and with attaining clinical remission, endoscopic improvement, and symptomatic remission at week 52 (all P < .05).ConclusionBowel urgency-related symptoms, assessed by the IBDQ, were improved in patients receiving vedolizumab vs placebo.Keywords: Clinical Remission, Endoscopic Outcomes, Health-Related Quality of Life, Inflammatory Bowel Disease Questionnaire, Patient-Reported Outcomes Introduction Ulcerative colitis (UC) is a chronic, progressive disease of the gastrointestinal tract and has a relapsing–remitting course.1, 2, 3 Often beginning in early adulthood, UC imposes a lifelong burden, affecting health-related quality of life (HRQoL) and work productivity, with symptoms including increased stool frequency, rectal bleeding, fatigue, bowel urgency, and incontinence.4, 5, 6, 7 Among these, bowel urgency — the sudden or immediate need to have a bowel movement — is frequently cited as one of the most burdensome symptoms for people with UC, and the symptom that patients most want improved.7, 8, 9 The mechanism of bowel urgency in UC is believed to include inflammatory changes in the rectum, which may be linked to hypersensitivity and reduced rectal compliance.7,10 Bowel urgency is reported by more than 80% of people with UC, with 25% to 50% of people experiencing urgency at least once daily.9 This symptom contributes to considerable disease-related stress; may involve episodes of fecal incontinence; and often involves the need for adaptive behaviors such as bathroom mapping, carrying clean-up kits, wearing adult diapers, briefs, or pads, and avoiding locations without public bathrooms.9,11 Despite its impact, people with UC may not discuss bowel urgency owing to embarrassment, and health-care providers may not address the symptom because of limited awareness of validated tools or patient disclosure of active symptoms.7,12,13 The American College of Gastroenterology clinical guidelines for UC include the absence of bowel urgency as a criterion for disease remission; however, bowel urgency is not captured in the Mayo score, which remains the most widely used measure of UC disease activity in clinical trials.14,15 The US Food and Drug Administration (FDA) updated its guidance in 2022 to recommend including bowel urgency as an exploratory end point in clinical trials, underscoring the need for responsive and reliable patient-reported outcome (PRO) measures of bowel urgency.16 Currently used PRO measures that assess bowel urgency include the Urgency Numeric Rating Scale,17 the Symptoms and Impacts Questionnaire-UC,18 and the UC PRO Signs and Symptoms Diary.19 The Inflammatory Bowel Disease Questionnaire (IBDQ) — the most commonly used tool for assessing HRQoL in clinical trials — can also be used to assess bowel urgency.20,21 The IBDQ is a 32-item questionnaire that evaluates the following four domains: bowel symptoms, systemic symptoms, emotional function, and social function.22,23 Within these domains are items that can be used as proxies for bowel urgency, and data analyzing these items have been used to report improvements in bowel urgency symptoms in people receiving advanced therapies for inflammatory bowel disease (IBD).21,24 Vedolizumab is indicated for the treatment of adults with moderate to severe UC, with safety and efficacy supported by data from several large, multicenter trials, including GEMINI 1, VISIBLE 1, and VARSITY.25, 26, 27, 28, 29 The IBDQ was used as the primary instrument to assess HRQoL during these 3 trials, and multiple subanalyses have been performed using PRO measures from the Mayo score or the IBDQ. A post hoc analysis from 2022, which pooled IBDQ results from 6 phase 3 studies for vedolizumab (3 in patients with UC; 3 in patients with Crohn’s disease), showed improvements in overall HRQoL.30 However, to our knowledge, prior research has not evaluated the impact of vedolizumab using the bowel urgency-related items from the IBDQ, and there is limited research on the effect of vedolizumab on bowel urgency to date.31 This post hoc analysis aimed to address this research gap by assessing the impact of vedolizumab on bowel urgency using selected bowel urgency-related IBDQ items evaluated during the GEMINI 1, VISIBLE 1, and VARSITY trials of adults with UC. Methods Study Design This post hoc analysis of the GEMINI 1 (NCT00783718), VISIBLE 1 (NCT02611830), and VARSITY (NCT02497469) trials included adults with UC who received vedolizumab or placebo and completed the IBDQ at baseline and during follow-up visits. The study designs of GEMINI 1, VISIBLE 1, and VARSITY have been described previously.27, 28, 29 In brief, GEMINI 1 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of the intravenous (IV) formulation of vedolizumab for induction and maintenance therapy in adults with moderate to severe UC. Patients received vedolizumab 300 mg IV or placebo at weeks 0 and 2. Those who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab IV every 8 weeks (Q8W) or every 4 weeks, or to switch to placebo for up to 52 weeks. VISIBLE 1 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of the subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adults with moderate to severe UC. Patients received vedolizumab 300 mg IV at weeks 0 and 2. At week 6, patients with clinical response were randomly assigned to maintenance treatment with vedolizumab 108 mg SC every 2 weeks, vedolizumab 300 mg Q8W IV, or placebo. VARSITY was a phase 3b, double-blind, double-dummy, randomized head-to-head trial comparing the IV formulation of vedolizumab with adalimumab in adults with moderate to severe UC. Patients received vedolizumab 300 mg IV on day 1, and at weeks 2 and 6, followed by dosing Q8W, or adalimumab 160 mg SC at week 1, 80 mg at week 2, and 40 mg every 2 weeks until week 50. Assessments and Outcomes Three bowel urgency-related items from the IBDQ were analyzed; each item was scored from 1 (all of the time) to 7 (none of the time). These included the following: Question 11 (“How often during the last 2 weeks have you been troubled because of fear of not finding a washroom?”); Question 16 (“How often during the last 2 weeks have you had to avoid attending events where there was no washroom close at hand?”); and Question 26 (“How much of the time during the last 2 weeks have you been troubled by accidental soiling of your underpants?”). These items were selected based on their conceptual relevance to key dimensions of bowel urgency, including psychological impact (Question 11), behavioral adaptation (Question 16), and urgency-associated incontinence (Question 26), and were informed by prior clinical trial analyses using individual IBDQ items to assess urgency-related symptoms (eg, Questions 11 and 16 in a tofacitinib phase 3 maintenance trial and Question 16 in a guselkumab phase 3 induction trial).21,24 The inclusion of Question 26 was further supported by evidence demonstrating that fecal incontinence is experienced by up to 45% of patients and significantly more likely among patients with UC who experience bowel urgency.32,33 In this post hoc analysis, bowel urgency resolution was defined as a score of 7 (ie, symptom-free) on each of the 3 bowel urgency-related IBDQ questions. Bowel urgency composite score was defined as the combined score to these 3 questions (range 3–21, with higher scores indicating less burdensome symptoms). Baseline was defined as the day of screening visit or day 1 of the study. In all 3 studies, IBDQ was assessed at baseline and weeks 6, 26 (or week 30 for VARSITY), and 52. The primary outcomes of this post hoc analysis were change from baseline to weeks 6, 26 (or week 30 for VARSITY), and 52 in the bowel urgency composite score, as well as the proportion of patients with bowel urgency resolution at week 52. The exploratory outcomes included percentage change from baseline to weeks 6, 26 (or week 30 for VARSITY), and 52 in bowel urgency composite score for the overall patient population and patients stratified by anti–tumor necrosis factor (anti-TNF)-α treatment status (naïve [no prior anti-TNF-α treatment] vs experienced [prior anti-TNF-α treatment]), disease activity (moderate [total Mayo score: 6–8] vs severe [total Mayo score: 9–12]). Patients who received vedolizumab IV could have received Q8W or every 4 weeks dosing; therefore, a subgroup analysis of treatment arms was performed to evaluate only those patients who received vedolizumab Q8W IV vs placebo. We also assessed percentage change from baseline to weeks 6, 26 (or week 30 for VARSITY), and 52 in stool frequency subscore (SFS) and rectal bleeding subscore (RBS); proportion of patients with bowel urgency resolution at week 52, stratified by anti-TNF-α treatment status, disease activity, and treatment arm (vedolizumab Q8W IV vs placebo); and proportion of patients with bowel urgency resolution at week 6 who attained clinical and endoscopic outcomes at week 6 or week 52. Clinical and endoscopic outcomes included the following: clinical remission (defined as a total Mayo score of ≤2 points and no individual subscore of >1 point); clinical response (defined as a reduction in the total Mayo score of ≥3 points and of ≥30% from baseline in GEMINI 1 and VISIBLE 1, or a reduction in partial Mayo score of ≥2 points and of ≥25% from baseline in VARSITY, with an accompanying decrease in RBS of ≥1 point or absolute RBS of ≤1 point); corticosteroid-free remission (defined as discontinuation of oral corticosteroids and clinical remission at week 52, assessed in patients receiving oral corticosteroids at baseline); endoscopic improvement (defined as Mayo endoscopic subscore of ≤1; termed ‘mucosal healing’ in GEMINI 1); and symptomatic remission (defined as an RBS of 0 and SFS of ≤1). The associations between change in bowel urgency composite score and SFS, as well as RBS at all time points were also evaluated as exploratory outcomes. Data Analysis Data were pooled across the GEMINI 1, VISIBLE 1, and VARSITY studies for all outcomes. Demographic and clinical characteristics were summarized with descriptive statistics by study visit and treatment group. Number, mean, standard deviation (SD), median, minimum, and maximum were reported for continuous variables. Number, frequency, and percentage were reported for categorical variables. Change in bowel urgency composite scores from baseline at each postbaseline visit were analyzed using analysis of covariance, with treatment and baseline value as covariates. For bowel urgency resolution at week 52, the number, frequency, and percentage of responders were summarized by treatment group and strata (anti-TNF-α exposure, disease activity, treatment arm [vedolizumab Q8W IV vs placebo]). Differences in response rates between vedolizumab and placebo were calculated with 95% confidence intervals. Correlations between change from baseline in bowel urgency composite score and changes from baseline in SFS and RBS were calculated using Pearson correlation. Patients were categorized by whether or not they had bowel urgency resolution and whether or not they attained each clinical outcome at each time point. Statistical significance was evaluated using a test of difference in proportions between groups. As these analyses were conducted post hoc, no adjustments for multiple comparisons were made. Results Participants In total, 1225 participants were included in this post hoc analysis. Participant demographics and baseline characteristics are shown in Table 1. Table 1Participant Demographics and Baseline CharacteristicsDemographic or characteristicOverall N = 1,225aVedolizumab n = 600bPlacebo n = 129bAge, y, mean (SD)40.4 (13.4)40.5 (13.6)41.6 (12.8)Sex, n (%) Male726 (59)351 (59)70 (54)Duration of UC, y, mean (SD)7.2 (6.7)7.3 (6.6)7.2 (6.7)Total Mayo score, mean (SD)c8.65 (1.66)8.63 (1.64)8.46 (1.74)Categorical total Mayo score, n (%)c Mild (0–5)27 (2)10 (2)7 (5) Moderate (6–8)543 (44)277 (46)60 (47) Severe (9–12)652 (53)312 (52)62 (48)Concomitant corticosteroids, n (%)c436 (36)159 (27)62 (48)Concomitant medication, n (%)c Neither glucocorticoids nor immunosuppressants700 (57)417 (70)42 (33) Glucocorticoids only236 (19)68 (11)32 (25) Immunosuppressants only165 (14)77 (13)32 (25) Both glucocorticoids and immunosuppressants117 (9.6)33 (5.5)23 (18)Fecal calprotectin, mg/kg, mean (SD)c2441.45 (4200.33)2660.44 (5153.01)2058.64 (2621.26)Prior anti-TNF-α treatment, n (%)c437 (36)164 (28)41 (32)aCombined data from patients receiving vedolizumab or placebo, and patients recording as ‘missing’ owing to not receiving treatment at the week 52 visit.bPatients are grouped based on recorded treatment at week 52.cData were missing for the following variables in the overall, vedolizumab, and placebo groups, respectively: total Mayo score (3, 1, and 0 patients), categorical total Mayo score (3, 1, and 0 patients), concomitant corticosteroid use (7, 5, and 1 patients), concomitant medication use (7, 5, and 1 patients), fecal calprotectin (81, 41, and 4 patients), and prior anti-TNF-α, treatment (7, 5, and 0 patients). Participant Demographics and Baseline Characteristics Combined data from patients receiving vedolizumab or placebo, and patients recording as ‘missing’ owing to not receiving treatment at the week 52 visit. Patients are grouped based on recorded treatment at week 52. Data were missing for the following variables in the overall, vedolizumab, and placebo groups, respectively: total Mayo score (3, 1, and 0 patients), categorical total Mayo score (3, 1, and 0 patients), concomitant corticosteroid use (7, 5, and 1 patients), concomitant medication use (7, 5, and 1 patients), fecal calprotectin (81, 41, and 4 patients), and prior anti-TNF-α, treatment (7, 5, and 0 patients). Among all participants, 53% had severe UC and 44% had moderate UC. Overall, 36% of participants were anti-TNF-α treatment-experienced and 64% were anti-TNF-α treatment-naïve. Disease activity and anti-TNF-α exposure were similar between vedolizumab and placebo groups. Mean (SD) disease duration at baseline was similar in participants who received vedolizumab or placebo (7.26 [6.57] vs 7.18 [6.65] years, respectively). Mean (SD) bowel urgency composite score at baseline was similar in participants who received vedolizumab or placebo (12.16 [4.51] vs 12.82 [4.55], respectively). Bowel Urgency Composite Score Mean change from baseline in bowel urgency composite scores was higher in those who received vedolizumab than placebo at all time points (mean change at week 52: vedolizumab, 6.0; placebo, 2.9; Figure 1). At all time points, participants receiving vedolizumab had greater mean percentage changes from baseline in bowel urgency composite scores than the placebo group overall and when stratified by anti-TNF-α status, disease activity, or treatment arm (vedolizumab Q8W IV vs placebo; Figure 2A–D; Supplementary Figure). Mean (95% CI) change from baseline in bowel urgency composite scores at weeks 6, 26/30,a and 52. aData were reported at week 26 for GEMINI 1 and VISIBLE 1, and week 30 for VARSITY. bN numbers reflect overall study analysis population and may not contribute to composite score changes at each timepoint. CI, confidence interval. Mean percentage change from baseline in bowel urgency composite score at weeks 6, 26/30,a and 52 for the overall patient population (A); and patients stratified by treatment arm (vedolizumab Q8W IV vs placebo)b (B), disease activity (C), and anti-TNF-α treatment status (D). Patients may move between the vedolizumab and placebo treatment groups based on their actual treatment pattern. Patients may not be included in any given visit owing to missing outcome data or treatment arm information. a Data were reported at week 26 for GEMINI 1 and VISIBLE 1 but week 30 for VARSITY. bOnly for patients who received vedolizumab Q8W IV vs placebo. cN numbers reflect overall study analysis population and may not contribute to composite score changes at each timepoint. dModerate UC, total Mayo score: 6 to 8; severe UC, total Mayo score: 9 to 12. Bowel Urgency Resolution At week 52, a greater proportion of participants in the vedolizumab group had bowel urgency resolution than the placebo group (44% vs 22%; Figure 3). When stratified into subgroups, a greater proportion of participants in the vedolizumab group who were anti-TNF-α treatment-naïve had bowel urgency resolution than those who were anti-TNF-α treatment-experienced (46% vs 37%). A higher proportion of participants in the vedolizumab group who had moderate disease at baseline had bowel urgency resolution than participants with severe disease (49% vs 39%). In addition, a higher proportion of participants who received vedolizumab Q8W IV had bowel urgency resolution than those in the placebo group (42% vs 22%). Proportion (95% CI) of patients who had bowel urgency resolutiona at week 52. CI, confidence interval. Patients with missing anti-TNF-α treatment exposure status and patients with mild disease activity at baseline were excluded from the analysis. aDefined as a score of 7 (ie, symptom-free), on each of the 3 bowel urgency-related IBDQ questions. bOnly for patients who received vedolizumab Q8W IV vs placebo. Association Between Bowel Urgency and Endoscopic and Clinical Outcomes SFS and RBS decreased from baseline through week 52. At all time points, an increase in bowel urgency composite score exhibited low to moderate correlations with reduction in SFS and RBS (week 52 Pearson correlation coefficient, −0.45 and −0.35, respectively; Table 2). The proportion of participants who achieved the following clinical outcomes at week 6 was significantly higher among those with bowel urgency resolution at week 6 than those without: clinical remission (51% vs 17%), clinical response (96% vs 69%), endoscopic improvement (26% vs 7%), fecal calprotectin ≤250 mg/kg (48% vs 35%), and symptomatic remission (81% vs 38%; Figure 4A). Similarly, the proportion of participants who achieved clinical outcomes at week 52 was higher in those with bowel urgency resolution at week 6 than those without (clinical remission, endoscopic improvement, symptomatic remission; Figure 4B); however, clinical response, corticosteroid-free remission, and fecal calprotectin ≤250 mg/kg did not reach statistical significance. Table 2Mean Percentage Change From Baseline in SFS and RBS, and Correlation Between Change From Baseline in Bowel Urgency Composite Score and Changes From Baseline in SFS or RBS at Weeks 6, 26/30,a and 52 in Patients Who Received VedolizumabWeek 6Week 26/30aWeek 52SFS Change from baseline, %−43.96−64.73−72.46 Pearson correlation coefficient (95% CI)b−0.34 (−0.4, −0.27)−0.45 (−0.5, −0.39)−0.45 (−0.51, −0.38)RBS Change from baseline, %−68.18−83.12−86.36 Pearson correlation coefficient (95% CI)b−0.31 (−0.38, −0.25)−0.36 (−0.42, −0.29)−0.35 (−0.42, −0.28)Lower SFS and RBS indicate less burdensome bowel urgency symptoms.CI, confidence interval.aData were reported at week 26 for GEMINI 1 and VISIBLE 1 but week 30 for VARSITY.bVersus change from baseline in bowel urgency composite score. Mean Percentage Change From Baseline in SFS and RBS, and Correlation Between Change From Baseline in Bowel Urgency Composite Score and Changes From Baseline in SFS or RBS at Weeks 6, 26/30,a and 52 in Patients Who Received Vedolizumab Lower SFS and RBS indicate less burdensome bowel urgency symptoms. CI, confidence interval. Data were reported at week 26 for GEMINI 1 and VISIBLE 1 but week 30 for VARSITY. Versus change from baseline in bowel urgency composite score. Association between bowel urgency resolution at week 6 and clinical outcomes at week 6 (A) and week 52 (B). Corticosteroid-free remission was defined as discontinuation of oral corticosteroids, followed by clinical remission at week 52, assessed in participants who were using oral corticosteroids at baseline; data for this clinical outcome at week 6 were therefore not available. ∗∗P < .001; ∗P < .05; ns, not significant. Discussion Bowel urgency is increasingly recognized as one of the most burdensome symptoms for people with UC, strongly impacting HRQoL and daily functioning.7,9 Regulatory agencies, including the FDA and European Medicines Agency (EMA), now recommend incorporating bowel urgency as an exploratory end point in clinical trials of UC.16,25 Previous studies of other advanced therapies, such as tofacitinib and guselkumab, have reported improvements in urgency-related PROs measured using the IBDQ.20,21 In the GEMINI 1, VISIBLE 1, and VARSITY studies, vedolizumab was associated with greater improvements in HRQoL compared with placebo or adalimumab; however, bowel urgency was not specifically assessed in the primary analyses.27, 28, 29 The prevalence of bowel urgency in patients with UC and the efficacy of advanced therapies in reducing bowel urgency have been demonstrated in real-world settings, with variable outcomes across treatment classes. In the prospective SPARC IBD cohort study, bowel urgency symptoms showed generally minimal improvement across advanced therapies, with moderate to severe bowel urgency persisting in 16.9% of patients receiving anti-TNF-α treatments (adalimumab, certolizumab, infliximab, and golimumab) and 32.1% receiving non–anti-TNF-α treatments (ustekinumab, tofacitinib, and vedolizumab) at 12 months.34 In a real-world registry of tofacitinib-treated patients, normalization of bowel urgency was observed in 48% of patients at week 52 among those on maintenance therapy.35 A previous patient and physician survey study showed that bowel urgency is highly prevalent in patients with UC (98.5%) and remains so even during remission (65.9%).33 These findings highlight the importance of assessing bowel urgency as a clinically meaningful outcome when evaluating treatment efficacy in UC. This post hoc analysis demonstrates that patients receiving vedolizumab had reduced symptoms of bowel urgency than those receiving placebo, and these symptom improvements were sustained from week 6 to week 52. Indeed, a substantial proportion of patients (44%) receiving vedolizumab at any study dosing schedule had no bowel urgency symptoms by week 52. Similarly, 42% of patients receiving vedolizumab Q8W IV reached bowel urgency resolution. Collectively, these data support the effectiveness of vedolizumab in achieving sustained symptom improvement. The effectiveness of vedolizumab in improving bowel urgency was more pronounced in patients who were anti-TNFα-naïve than those who were anti-TNF-α-experienced. These findings are in line with prior studies reporting greater effectiveness of vedolizumab in anti-TNF-α-naïve than anti-TNF-α-experienced patients across clinical outcomes, including clinical remission and corticosteroid-free remission.36,37 A greater proportion of patients with moderate disease activity reached bowel urgency resolution than those with severe disease. This finding aligns with previous studies that have demonstrated that although vedolizumab is effective in both moderate and severe UC, patients with moderate disease have higher clinical remission rates than those with severe disease at baseline.38,39 Patients with severe disease in this analysis had greater percentage reductions from baseline in bowel urgency composite score than those with moderate disease; however, this finding may reflect the lower baseline scores (ie, more burdensome symptoms) in the severe disease group, which allowed a greater relative magnitude of improvement than in the moderate disease group. Here we also show that a reduction in bowel urgency symptoms was associated with improvements in clinical and endoscopic signs of UC. Improvements in bowel urgency composite scores of patients receiving vedolizumab correlated with improvements in SFS and RBS at all time points. Attainment at week 6 of clinical remission, clinical response, endoscopic improvement, fecal calprotectin ≤250 mg/kg, or symptomatic remission were each significantly associated with bowel urgency resolution at week 6 in patients who received vedolizumab, which suggests that early improvement in clinical and endoscopic outcomes is associated with early improvement in bowel urgency symptoms. The association between early bowel urgency resolution and clinical remission, endoscopic improvement, and symptomatic remission persisted to week 52. These sustained improvements in bowel urgency, alongside clinical and endoscopic outcomes, highlight the benefit of vedolizumab in addressing well-being in addition to delivering clinical improvements, with clinically meaningful outcomes observed as early as week 6. This post hoc analysis of a large, pooled patient population from 3 phase 3 clinical trials assessed outcomes at multiple time points up to 52 weeks, to provide insights into the effects of vedolizumab on the historically underreported outcome of bowel urgency. However, these findings should be considered within the following limitations. While data correlate the Urgency Numeric Rating Scale with IBDQ total score and bowel symptoms domain, and previous analyses have also used individual bowel urgency-related items from the IBDQ as proxies for bowel urgency,17,20,21 the combination of these items into a composite score has not been formally validated as a measure of bowel urgency. This may limit the interpretability and generalizability of the results from this study. Small subgroup sizes after stratification also warrant caution in interpreting statistical comparisons. Moreover, pooling data from 3 clinical trials with differences in study design, maintenance strategies, and comparator arms may have influenced the observed outcomes. For example, GEMINI 1 and VISIBLE 1 included rerandomization following induction, whereas VARSITY employed a treat-through design. In addition, the induction phase of VISIBLE 1 was open-label, whereas GEMINI 1 was double-blind. While these differences may introduce potential heterogeneity, preliminary analyses did not indicate that they meaningfully impacted the outcomes described here. Conclusion This post hoc analysis adds to the growing body of evidence supporting the efficacy of vedolizumab in improving not only clinical and endoscopic outcomes but also patient-reported symptoms of bowel urgency that are particularly burdensome and meaningful to individuals living with UC. Acknowledgments Authors’ Contributions Angelina E Collins: Analysis and interpretation of data, drafting, critically reviewing and approving the manuscript. Thais Gift: Conception and design, analysis and interpretation of data, drafting, and critically reviewing and approving the manuscript. Edward Kim: Conception and design, analysis and interpretation of data, drafting, and critically reviewing and approving the manuscript. Ian Robinson: Conception and design, analysis and interpretation of data, drafting, and critically reviewing and approving the manuscript. Footnotes Conflicts of Interest: These authors disclose the following: Angelina E Collins: Advisory board, speaker bureau, and consultant: AbbVie, Eli Lilly, Johnson & Johnson, Takeda Pharmaceuticals U.S.A., Inc; advisory board: Cristcot. Thais Gift, Edward Kim, and Ian Robinson: employees of Takeda Pharmaceuticals U.S.A., Inc and receive stock and/or stock options. The remaining authors disclose no conflicts. Funding: This study was sponsored by Takeda Pharmaceuticals U.S.A., Inc. Medical writing support was provided by Hera Wong of PharmaGenesis Cardiff, Cardiff, UK, and was funded by Takeda Pharmaceuticals U.S.A., Inc, in accordance with Good Publication Practice (GPP 2022) guidelines (www.ismpp.org/gpp-2022). Ethical Statement: The clinical trial protocols for GEMINI 1, VISIBLE 1, and VARSITY were approved by an institutional review board or ethics committee at each trial site, and all patients provided written informed consent. Data Transparency Statement: The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants' data supporting the results reported in this article, will be made available within 3 months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its deidentification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Reporting Guidelines: CONSORT. Material associated with this article can be found, in the online version, at https://doi.org/10.1016/j.gastha.2026.101109. Supplementary Materials Mean (SD) bowel urgency composite score at week 52 stratified by anti-TNF-α treatment status, disease activity, and treatment arm (vedolizumab Q8W IV vs placebo)a. aOnly for patients who received vedolizumab Q8W IV versus placebo. References